Corporate Presentation_Jan 2023_Final 天境.pdf

1、I-Mab BiopharmaPioneering the Next-Generation of Immuno-OncologyJanuary 2023|Pioneering the Next-Generation of Immuno-Oncology|Corporate Presentation January 2023DisclaimerThis presentation has been prepared by I-Mab(the“Company”)solely for information purpose.By viewing or accessing the information

2、 contained in this material,you hereby acknowledge andagree that no representations,warranties,or undertakings,express or implied,are made by the Company or any of its directors,shareholders,employees,agents,affiliates,advisors,orrepresentatives as to,and no reliance should be placed upon,the accura

3、cy,fairness,completeness,or correctness of the information or opinions presented or contained in this presentation.None of the Company or any of its directors,shareholders,employees,agents,affiliates,advisors,or representatives accept any responsibility whatsoever(in negligence or otherwise)for anyl

4、oss howsoever arising from any information presented or contained in this presentation or otherwise arising in connection with the presentation.The information presented or contained in thispresentation is subject to change without notice and its accuracy is not guaranteed.This presentation does not

5、 constitute an offer to sell or issue or an invitation or recommendation to purchase or subscribe for any securities of the Company for sale in the United States oranywhere else.No securities of the Company may be sold in the United States without registration with the United States Securities and E

6、xchange Commission(the“SEC”)or an exemptionfrom such registration pursuant to the Securities Act of 1933,as amended(the“Securities Act”)and the rules and regulations thereunder.No part of this presentation shall form the basis of orbe relied upon in connection with any contract or investment decisio